This state-of-the-art review summarizes contemporary insights into diabetic cardiomyopathy, focusing on cardiac energy metabolism, structural changes, and outcomes with new glucose-lowering therapies.
This review highlights the contributions of non-invasive technologies to understanding diabetic cardiomyopathy and the impact of new glucose-lowering therapies on cardiovascular outcomes.
Heart failure is a major cause of morbidity and mortality in type 2 diabetes. Type 2 diabetes contributes to the development of heart failure through a variety of mechanisms, including disease-specific myocardial structural, functional and metabolic changes. This review will focus on the contemporary contributions of state of the art non-invasive technologies to our understanding of diabetic cardiomyopathy, including data on cardiac disease phenotype, cardiac energy metabolism and energetic deficiency, ectopic and visceral adiposity, diabetic liver disease, metabolic modulation strategies and cardiovascular outcomes with new classes of glucose-lowering therapies.
Levelt et al. (Tue,) conducted a review in Diabetic cardiomyopathy in type 2 diabetes. Metabolic interventions and glucose-lowering therapies was evaluated. This state-of-the-art review summarizes contemporary insights into diabetic cardiomyopathy, focusing on cardiac energy metabolism, structural changes, and outcomes with new glucose-lowering therapies.